Design and synthesis of novel conformationally constrained 7,12-dihydrodibenzo[b,h][1,6] naphthyridine and 7H-Chromeno[3,2-c] quinoline derivatives as topoisomerase I inhibitors: In vitro screening, molecular docking and ADME predictions

Bioorg Chem. 2021 Jul 16;115:105174. doi: 10.1016/j.bioorg.2021.105174. Online ahead of print.ABSTRACTNovel non-camptothecin (non-CPT) class of conformationally constrained, hitherto unknown 7,12-dihydrodibenzo[b,h][1,6] naphthyridine and 7H-Chromeno[3,2-c] quinoline derivatives have been designed, synthesized and evaluated for anti-cancer activity. In vitro anti-proliferation evaluation against human cancer cell lines (A549 and MCF-7) exhibited significant cytotoxicity. Among the derivatives (8-24), 8 (IC50 0.44 μM and IC50 0.62 μM) and 12 (IC50 0.69 μM and IC50 0.54 μM) were identified as the most promising candidate against A-549 and MCF-7 cancer cell lines respectively. Topo I inhibitory activity of 8 and 12 suggested that, they may be developed as potential anti-cancer molecules in future and rationalized by docking analysis with effective binding modes. Further, in silico ADME prediction studies of all derivatives were found promising, signifying the drug like properties. In precise, the present investigation displays a new strategy to synthesize and emphasis on anticancer activities of conformationally constrained dibenzo[b,h][1,6] naphthyridine derivatives and Chromeno[3,2-c] quinoline derivatives in the context of cancer drug development and refinement.PMID:34314913 | DOI:10.1016/j.bioorg.2021.105174

Source: Bioorganic Chemistry - July 27, 2021 Category: Chemistry Authors: Ramakant A Kardile Aniket P Sarkate Avinash S Borude Rajendra S Mane Deepak K Lokwani Shailee V Tiwari Rajaram Azad Prasad V L S Burra Shankar R Thopate Source Type: research